Trial Profile

A Multi-center, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HRS 9531 (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Fujian Shengdi Pharmaceutical

Most Recent Events

16 Jun 2025 According to Kailera Therapeutics media release, data from this trial will be presented at the 85th Scientific Sessions of the American Diabetes Association (ADA), and will be published online in the journal Diabetes
30 Apr 2025 Status changed from active, no longer recruiting to completed.
21 Dec 2023 Planned End Date changed from 9 Sep 2024 to 20 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com